PEGylation of cyanovirin-N, an entry inhibitor of HIV

Advanced Drug Delivery Reviews

Volumn 60, Issue 1, 2008, Pages 79-87

  Zappe, H ^a   Snell, M E ^b   Bossard, M J ^a  

^a NEKTAR THERAPEUTICS   (United States)

^b HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

CV N; Cyanovirin N; PEG; PEGylated CV N

Indexed keywords

DISEASES; DRUG PRODUCTS; ENZYME INHIBITION; IMMUNOLOGY; MUTAGENS;

CYANOBACTERIAL ORIGIN; PLASMA HALF-LIFE; POTENT INHIBITORS; VIRAL INFECTION;

POLYETHYLENE GLYCOLS;

CYANOVIRIN N; CYSTEINE; GLUTAMINE; MACROGOL; MALEIMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG PURIFICATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BACTERIAL PROTEINS; CARRIER PROTEINS; DRUG COMPOUNDING; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; POLYETHYLENE GLYCOLS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 36549005026     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.05.016     Document Type: Review

References (44)

1. Quinn T.C., and Overbaugh J. HIV/AIDS in women: an expanding epidemic. Science 308 (2005) 1582-1583
2. Lalezari J.P., Lewis S., Subramanian G.M., Krawiec R., and Delmedico M.K. Parenteral inhibitors of HIV entry in current development. J. Viral Entry 2 (2006) 48-56
3. Girard M.P., Osmanov S.K., and Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 (2006) 4062-4081
4. FDA approves first drug in new class of HIV treatments for HIV infected adults and children with advanced disease (2003). http://www.fda.gov/bbs/topics/news/2003/new00879.html cited; Available from: http://www.fda.gov/bbs/topics/news/2003/new00879.html
5. Balzarini J., Van Laethem K., Hatse S., Vermeire K., De Clercq E., Peumans W., Van Damme E., Vandamme A.M., Bolmstedt A., and Schols D. Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. J. Virol. 78 (2004) 10617-10627
6. Briz V., Poveda E., and Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 57 (2006) 619-627
7. Boyd M.R., Gustafson K.R., McMahon J.B., Shoemaker R.H., O'Keefe B.R., Mori T., Gulakowski R.J., Wu L., Rivera M.I., Laurencot C.M., Currens M.J., Cardellina II J.H., Buckheit Jr. R.W., Nara P.L., Pannell L.K., Sowder II R.C., and Henderson L.E. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob. Agents Chemother. 41 (1997) 1521-1530
8. Pauwels R., De Clercq E., Quinn T.C., and Overbaugh J. Development of vaginal microbicides for the prevention of heterosexual transmission of HIV. HIV/AIDS in women: an expanding epidemic. J. Acquir. Immune Defic. Syndr. Human Retrovirol. 11 (1996) 211-221
9. Dey B., Lerner D.L., Lusso P., Boyd M.R., Elder J.H., and Berger E.A. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J. Virol. 74 (2000) 4562-4569
10. Helle F., Wychowski C., Vu-Dac N., Gustafson K.R., Voisset C., and Dubuisson J. Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281 (2006) 25177-25183
11. O'Keefe B.R., Smee D.F., Turpin J.A., Saucedo C.J., Gustafson K.R., Mori T., Blakeslee D., Buckheit R., and Boyd M.R. Potent anti-influenza activity of cyanovirin-N and interactions with viral hemagglutinin. Antimicrob. Agents Chemother. 47 (2003) 2518-2525
12. Barrientos L.G., O'Keefe B.R., Bray M., Sanchez A., Gronenborn A.M., and Boyd M.R. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 58 (2003) 47-56
13. Barrientos L.G., Matei E., Lasala F., Delgado R., and Gronenborn A.M. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Protein Eng. Des. Sel. 19 (2006) 525-535
14. Gustafson K.R., Sowder II R.C., Henderson L.E., Cardellina II J.H., McMahon J.B., Rajamani U., Pannell L.K., and Boyd M.R. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Biochem. Biophys. Res. Commun. 238 (1997) 223-228
15. Bewley C.A., Gustafson K.R., Boyd M.R., Covell D.G., Bax A., Clore G.M., and Gronenborn A.M. Solution structure of cyanovirin-N, a potent HIV-inactivating protein. Nat. Struct. Biol. 5 (1998) 571-578
16. Yang F., Bewley C.A., Louis J.M., Gustafson K.R., Boyd M.R., Gronenborn A.M., Clore G.M., and Wlodawer A. Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping. J. Mol. Biol. 288 (1999) 403-412
17. Balzarini J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res. 71 (2006) 237-247
18. Botos I., and Wlodawer A. Proteins that bind high-mannose sugars of the HIV envelope. Prog. Biophys. Mol. Biol. 88 (2005) 233-282
19. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., Cornelissen I.L., Nottet H.S., KewalRamani V.N., Littman D.R., Figdor C.G., and van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100 (2000) 587-597
20. Nguyen D.G., and Hildreth J.E. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 33 (2003) 483-493
21. Bewley C.A., and Otero-Quintero S. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J. Am. Chem. Soc. 123 (2001) 3892-3902
22. Bolmstedt A.J., O'Keefe B.R., Shenoy S.R., McMahon J.B., and Boyd M.R. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol. Pharmacol. 59 (2001) 949-954
23. Geyer H., Holschbach C., Hunsmann G., and Schneider J. Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J. Biol. Chem. 263 (1988) 11760-11767
24. Leonard C.K., Spellman M.W., Riddle L., Harris R.J., Thomas J.N., and Gregory T.J. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265 (1990) 10373-10382
25. Mori T., and Boyd M.R. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob. Agents Chemother. 45 (2001) 664-672
26. Giomarelli B., Provvedi R., Meacci F., Maggi T., Medaglini D., Pozzi G., Mori T., McMahon J.B., Gardella R., and Boyd M.R. The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS 16 (2002) 1351-1356
27. Mori T., Gustafson K.R., Pannell L.K., Shoemaker R.H., Wu L., McMahon J.B., and Boyd M.R. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Protein Expr. Purif. 12 (1998) 151-158
28. Liu X., Lagenaur L.A., Simpson D.A., Essenmacher K.P., Frazier-Parker C.L., Liu Y., Tsai D., Rao S.S., Hamer D.H., Parks T.P., Lee P.P., and Xu Q. Engineered vaginal lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob. Agents Chemother. 50 (2006) 3250-3259
29. Pusch O., Boden D., Hannify S., Lee F., Tucker L.D., Boyd M.R., Wells J.M., and Ramratnam B. Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. J. Acquir. Immune Defic. Syndr. (1999) 40 (2005) 512-520
30. Sexton A., Drake P.M., Mahmood N., Harman S.J., Shattock R.J., and Ma J.K. Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB J. 20 (2006) 356-358
31. Mori T., Shoemaker R.H., McMahon J.B., Gulakowski R.J., Gustafson K.R., and Boyd M.R. Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells. Biochem. Biophys. Res. Commun. 239 (1997) 884-888
32. Roberts M.J., Bentley M.D., and Harris J.M. Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54 (2002) 459-476
33. Veronese F.M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 22 (2001) 405-417
34. Katre N.V. The conjugation of proteins with polyethylene glycol and other polymers. Altering properties of proteins to enhance their therapeutic potential. Adv. Drug Deliv. Rev. 10 (1993) 91-114
35. Bewley C.A., and Otero-Quintero S. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J. Am. Chem. Soc. 123 (2001) 3892-3902
36. Sambrook J., and Russell D.W. Molecular Cloning. A laboratory manual (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor
37. In: Ausubel F.M., Brent R., Kingston R.E., Moore D.D., Seidman J.J., Smith J.A., and Struhl K. (Eds). Current protocols in molecular biology vol. 1 (1988), John Wiley, New York
38. Shin S.U., and Morrison S.L. Production and properties of chimeric antibody molecules. Methods Enzymol. 178 (1989) 459-476
39. Barrientos L.G., Louis J.M., Botos I., Mori T., Han Z., O'Keefe B.R., Boyd M.R., Wlodawer A., and Gronenborn A.M. The domain-swapped dimer of cyanovirin-N is in a metastable folded state: reconciliation of X-ray and NMR structures. Structure 10 (2002) 673-686
40. Laakso M.M., and Doms R.W. The molecular basis of HIV entry and its inhibition. J. Viral Entry 2 (2006) 4-12
41. Reeves J.D., and Piefer A.J. Emerging drug targets for antiretroviral therapy. Drugs 65 (2005) 1747-1766
42. Turpin J.A. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11 (2002) 1077-1097
43. Patterson B.K., Landay A., Andersson J., Brown C., Behbahani H., Jiyamapa D., Burki Z., Stanislawski D., Czerniewski M.A., and Garcia P. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am. J. Pathol. 153 (1998) 481-490
44. Witkin S.S. Immunology of the vagina. Clin. Obstet. Gynecol. 36 (1993) 122-128